Back to Browse Journals » Pharmacogenomics and Personalized Medicine » Volume 5

Individualization of antiretroviral therapy

Authors Pavlos R, Phillips EJ

Published Date December 2011 Volume 2012:5 Pages 1—17

DOI http://dx.doi.org/10.2147/PGPM.S15303

Published 29 December 2011

Rebecca Pavlos, Elizabeth J Phillips
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia

Abstract: Antiretroviral therapy (ART) has evolved considerably over the last three decades. From the early days of monotherapy with high toxicities and pill burdens, through to larger pill burdens and more potent combination therapies, and finally, from 2005 and beyond where we now have the choice of low pill burdens and once-daily therapies. More convenient and less toxic regimens are also becoming available, even in resource-poor settings. An understanding of the individual variation in response to ART, both efficacy and toxicity, has evolved over this time. The strong association of the major histocompatibility class I allele HLA-B*5701 and abacavir hypersensitivity, and its translation and use in routine HIV clinical practice as a predictive marker with 100% negative predictive value, has been a success story and a notable example of the challenges and triumphs in bringing pharmacogenetics to the clinic. In real clinical practice, however, it is going to be the exception rather than the rule that individual biomarkers will definitively guide patient therapy. The need for individualized approaches to ART has been further increased by the importance of non-AIDS comorbidities in HIV clinical practice. In the future, the ideal utilization of the individualized approach to ART will likely consist of a combined approach using a combination of knowledge of drug, virus, and host (pharmacogenetic and pharmacoecologic [factors in the individual's environment that may be dynamic over time]) information to guide the truly personalized prescription. This review will focus on our knowledge of the pharmacogenetics of the efficacy and toxicity of currently available antiretroviral agents and the current and potential utility of such information and approaches in present and future HIV clinical care.

Keywords: HIV, pharmacogenetics, pharmacogenomics, personalized medicine, antiretroviral

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Boceprevir and personalized medicine in hepatitis C virus infection

Habersetzer F, Leboeuf C, Doffoël M, Baumert TF

Pharmacogenomics and Personalized Medicine 2012, 5:125-137

Published Date: 26 September 2012

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy

Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL

Therapeutics and Clinical Risk Management 2012, 8:377-384

Published Date: 17 September 2012

Role of pharmacogenomics in the treatment of tuberculosis: a review

Ramachandran G, Swaminathan S

Pharmacogenomics and Personalized Medicine 2012, 5:89-98

Published Date: 13 September 2012

Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent

AL-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK

Pharmacogenomics and Personalized Medicine 2012, 5:99-111

Published Date: 7 September 2012

The role of genetics in pre-eclampsia and potential pharmacogenomic interventions

Williams PJ, Morgan L

Pharmacogenomics and Personalized Medicine 2012, 5:37-51

Published Date: 20 January 2012

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009